Rezolute, Inc. (RZLT), a late-stage biopharmaceutical company focused on rare disease treatments, announced the pricing of an underwritten public offering.
The offering includes approximately 20.8 million shares of common stock at $3.25 per share, along with pre-funded warrants for 6.9 million shares offered at $3.249 per warrant. Combined, the gross proceeds are expected to total around $90 million before expenses. The company has also granted underwriters a 30-day option to purchase up to 4.15 million additional shares.
All securities in the offering will be issued by Rezolute, with the closing anticipated around April 24, 2025, pending customary conditions. The deal includes backing from both new and existing institutional investors such as Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and Nantahala Capital.
Rezolute plans to use the proceeds for R&D, general corporate purposes, and working capital. The securities are offered under a shelf registration statement filed with and declared effective by the SEC in November 2023. The offering will be conducted via a prospectus supplement available through the SEC's website or directly from the underwriters.
Wednesday, RZLT closed at $3.97, marking a 27.65% decline. In after-hours trading, the stock edged up slightly to $3.98, reflecting a 0.25% increase on the Nasdaq Capital Market.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.